Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital ...

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...

In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Protara Therapeutics (TARA – Research ...

Investment analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Protara Therapeutics in a note issued to ...

Detailed price information for Virtus Lifesci Biotech Products ETF (BBP-A) from The Globe and Mail including charting and trades.

II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, March 13, 2025 (GLOBE NEWSWIRE) -- Paris, ...

Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

Commissions do not affect our editors' opinions or evaluations. Capital One combines the convenience of online banking with the features of a traditional bank. It’s known for its competitive ...